A Multicenter, Open Label Phase I/II Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma (MM) Patients
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 13 Aug 2018
Price : $35 *
At a glance
- Drugs Carfilzomib (Primary) ; Cyclophosphamide (Primary) ; Dexamethasone (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 01 Aug 2018 Planned End Date changed from 1 Jun 2019 to 1 Jun 2021.
- 01 Aug 2018 Status changed from recruiting to active, no longer recruiting.